Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma
The aldose reductase inhibitor Fidarestat has been noted to have efficacy in treating a variety of tumors. To define its role in hepatocellular carcinoma (HCC), we induced a HCC xenograft model in mice, which were treated with different doses of Fidarestat. The amounts of natural killer (NK) cells a...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier
2021-12-01
|
| Series: | Molecular Therapy: Oncolytics |
| Assuntos: | |
| Acceso en liña: | http://www.sciencedirect.com/science/article/pii/S237277052100084X |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|